A peptide-based assay discriminates individual antibody response to SARS-CoV-2

Immacolata Polvere; Serena Voccola; Gaetano Cardinale; Maurizio Fumi; Francesca Aquila; Alfredina Parrella; Jessica Raffaella Madera; Romania Stilo; Pasquale Vito; Tiziana Zotti

doi:10.1016/j.gendis.2021.01.008

您当前的位置：

首页 >

文章列表页 >

A peptide-based assay discriminates individual antibody response to SARS-CoV-2

Full-length article | 更新时间：2022-06-24

- A peptide-based assay discriminates individual antibody response to SARS-CoV-2
- A peptide-based assay discriminates individual antibody response to SARS-CoV-2
- Genes & Diseases 2022年9卷第1期
- 作者机构：
  
  1. Dipartimento di Scienze e Tecnologie, Università degli Studi del Sannio, Via dei Mulini snc,Benevento,Italy,82100
  2. Genus Biotech, Università degli Studi del Sannio, Via Appia s..c. Apollosa (BN),n,Italy,82030
  3. Azienda Ospedaliera San Pio, Via Pacevecchia, 53, Benevento (BN),Italy,82100
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2021.01.008
  中图分类号：
- 纸质出版日期：2022，
  
  网络出版日期：2022-1-1，
扫描看全文
Immacolata Polvere, Serena Voccola, Gaetano Cardinale, 等. A peptide-based assay discriminates individual antibody response to SARS-CoV-2[J]. Genes & Diseases, 2022,9(1).

Immacolata Polvere, Serena Voccola, Gaetano Cardinale, et al. A peptide-based assay discriminates individual antibody response to SARS-CoV-2[J]. Genes & Diseases, 2022,9(1).
Immacolata Polvere, Serena Voccola, Gaetano Cardinale, 等. A peptide-based assay discriminates individual antibody response to SARS-CoV-2[J]. Genes & Diseases, 2022,9(1). DOI： 10.1016/j.gendis.2021.01.008.

Immacolata Polvere, Serena Voccola, Gaetano Cardinale, et al. A peptide-based assay discriminates individual antibody response to SARS-CoV-2[J]. Genes & Diseases, 2022,9(1). DOI： 10.1016/j.gendis.2021.01.008.

摘要

Abstract

SARS-CoV-2 virus is responsible for the current worldwide coronavirus disease 2019 (COVID-19) pandemic

infecting millions of people and causing hundreds of thousands of deaths. Understanding the antibody response to SARS-CoV-2 is crucial for the development of vaccines

therapeutics and public health interventions. However

lack of consistency in methods used to monitor antibody response to SARS-CoV-2 leaves some uncertainty in our fine understanding of the human antibody response mounted following SARS-CoV-2 infection. We developed a peptide-based enzyme-linked immunosorbent assay (ELISA) by selecting 7 synthetic peptides from the spike

membrane

and nucleocapsid protein sequences of SARS-CoV-2

which effectively detects the antibody response mounted by all COVID-19 convalescent tested. Strikingly

the assay shows a profound difference in antibody response among individual subjects

which may have a significant impact on disease severity. Together

our results define an efficient and specific serological assay to consistently measure the antibody response following SARS-CoV-2 infection

as well as help the design of vaccine and therapeuticals for prevention and treatment of COVID-19.

关键词

Keywords

AntibodiesAssayCOVID-19ELISAPeptidesSARS-Cov-2

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery

Advances of CRISPR-Cas13 system in COVID-19 diagnosis and treatment

Single-cell transcriptome landscape and antigen receptor dynamic during SARS-CoV-2 vaccination

Pandemic COVID-19: Current status and challenges of antiviral therapies

Coronavirus disease 2019 (COVID-19): cytokine storms, hyper-inflammatory phenotypes, and acute respiratory distress syndrome